Nephrotoxicity of Iso-osmolar Iodixanol Compared with Nonionic Low-osmolar Contrast Media: Meta-analysis of Randomized Controlled Trials
Radiology2008Vol. 250(1), pp. 68–86
Citations Over TimeTop 1% of 2008 papers
Abstract
Iodixanol is not associated with a significantly reduced risk of CIN compared with the LOCM pooled together. However, in patients with intraarterial administration and renal insufficiency, iodixanol is associated with a reduced risk of CIN compared with iohexol, whereas no significant difference between iodixanol and other LOCM could be found.
Related Papers
- → Comparison of Contrast-Induced Nephrotoxicity of Iodixanol and Iopromide in Patients With Renal Insufficiency Undergoing Coronary Angiography(2011)34 cited
- → Comparison of Iodixanol and Ioversol for the Prevention of Contrast-Induced Nephropathy in Diabetic Patients After Coronary Angiography or Angioplasty(2009)29 cited
- → Current evidence on prevention and management of contrast-induced nephropathy(2007)30 cited
- → AS-217: Can the Use of an Iso-osmolar Contrast Agent (Iodixanol) Reduce the Incidence of Contrast-Induced Nephropathy Compared with a Low-Osmolar Contrast Agent (Iopromide)?(2010)
- → TCT-473 Contrast-induced nephropathy (CIN) in patients with renal impairment: Pooled data from three prospective, randomized studies comparing iodixanol 320 mg and iopamidol 370mg(2017)